The Therapeutic Effects of Psychedelics: 2A or Not 2A?-Part 2
Some studies reveal that serotonin 2A receptor activation may not be necessary for the potential therapeutic effects of psychedelics.
Neurochemistry
Are Prodrugs the Next Wave of Psychedelic Drug Development?
The path toward therapeutic psychedelic-based drugs is becoming clearer as scientists understand more about how they are processed in the body.
The Therapeutic Effects of Psychedelics: 2A or Not 2A? – Part 1
The serotonin 2A receptor is a major player in the psychedelic response, but it may not be the only one involved.
Glutamate’s Role in Rapidly-Acting Antidepressants
Despite differing pharmacodynamics, ketamine and serotonergic psychedelics may share downstream effects crucial to their rapid and sustained antidepressant activity.
Glow Time: PsychLight Brings a Powerful Tool to Psychedelic Research
This innovation may pave the way for pharmaceuticals that act like psychedelics at the 5-HT2A receptor but don’t have hallucinogenic effects.
Same But Different: Antidepressant Mechanisms of Psilocybin and Ketamine
Ketamine and psilocybin both exert rapid antidepressant effects. Could these effects be explained by a common mechanism that promotes neurogenesis?
Exploring the Role of Serotonin 2A Activation in LSD’s Effects on Empathy
A recent study indicates that the empathogenic effects of LSD may be independent of serotonin 2A receptor activation.
Enzymes Responsible for DMT Synthesis Coexist in Mammalian Brain Cells
Is DMT produced in the brain? The answer remains unclear, but this 2019 study provides striking evidence supporting the neural-DMT synthesis hypothesis.
Mouse Study Reveals New Details on Psilocybin’s Rewiring of the Brain
Changes in structural neuroplasticity start within 24 hours, are enduring, and may not be solely dependent on 5-HT2A.
Is Nitrous Oxide a Psychedelic Drug?
Despite its euphoric effects, nitrous oxide is not considered psychedelic.